• 1
    WHO. A Research Agenda for Childhood Tuberculosis. WHO/HTM/TB/2007.381. Geneva: WHO, 2007. Available at (last accessed: 1 August 2007).
  • 2
    WHO. Treatment of tuberculosis: Guidelines for National Programmes, 3rd edn. WHO/CDS/TB/2003.313. Geneva: WHO, 2003. Available at (last accessed: 30 November 2007).
  • 3
    CDC. Recommendations and Report. Treatment of tuberculosis. American Thoracic Society, CDC and Infectious Disease Society of America. MMWR Morb Mortal Wkly Rep 2003; 52 (RR11), 177. Available at (last accessed: 1 August 2007).
  • 4
    Starke JR, Munoz F. Tuberculosis. In: Nelson Textbook of Pediatrics, 16th edn, eds BehrmanRE KliegmanR JensonHB. Singapore: Harcourt Publishing International Co, 2000; 88597.
  • 5
    RNTCP. Status Report 2003. New Delhi: M/O Health and Family Welfare, Government of India, Nirman Bhawan, 2003.
  • 6
    Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, Lafont O. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989; 36: 395400.
  • 7
    Durand F, Jebrak G, Pessayre D, Fournier M. Hepatotoxicity of antitubercular treatments. Drug Saf 1996; 15: 394405.
  • 8
    Radde IC, MacLeod SM. Therapeutic and nontherapeutic research in children. In: Pediatric Pharmacology and Therapeutics, 2nd edn, eds RaddeIC, MacLeodSM. Missouri: Mosby Publ, 1993; 60411.
  • 9
    Roy V, Tekur U, Chopra K. Pharmacokinetics of pyrazinamide in children suffering from pulmonary tuberculosis. Int J Tuberc Lung Dis 1999; 3: 1337.
  • 10
    Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann NY Acad Sci 2001; 953: 15764.
  • 11
    Subbammal S, Krishnamurthy DV, Tripathy SP, Venkataraman P. Concentration of pyrazinamide attained in serum with different doses of the drug. Bull World Health Organ 1968; 39: 7714.
  • 12
    Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969; 50: 14458.
  • 13
    Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988; 32: 10024.
  • 14
    Conroy S, McIntyre J, Choonara I, Stephenson T. Drug trials in children: problems and the way forward. Br J Clin Pharmacol 2000; 49: 937.
  • 15
    Zhu M, Burman WJ, Steiner P, Stambaugh JJ, Ashkin D, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacother 2002; 22: 68695.
  • 16
    Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Microbiol Infect Dis 2004; 23: 24355.
  • 17
    Dickinson JM, Mitchison DA. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 1970; 51: 38996.
  • 18
    McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in an acidic environment in vitro. Am Rev Tuberc 1954; 70: 74854.